DEVELOPMENT AND MARKETING AUTHORISATION OF BIOSIMILARS IN EU

Main Article Content

SUHAS SHANKAR JOSHI
V. BALAMURALIDHARA
AKHILESH AKKI

Abstract

A biosimilar is an item with natural beginning that is exceptionally practically equivalent to and with the shortfall of clinically significant contrasts from a predominant supported organic item. Administrative rules will refresh as often as possible for biosimilar improvement and endorsement. Companies and their contracting partners interested in entering the biosimilar market should be aware of all biosimilar standards and hurdles so that they can answer swiftly to any questions. The biosimilar industry appears appealing due to the potential for cost savings and efficiency, but regulatory, technological, and legal hurdles remain. A marketing permission must be given by the governing agency before any pharmaceutical product can be placed on the market. The primary goal of obtaining marketing authorization is to verify that the product is safe and effective, as well as that it is a high-quality medicine. Biosimilars were approved for the first time in a regulated market in the globe, and they play a vital role in ensuring the safety, quality, and accessibility of human, veterinary, cosmetic, and biological products. The guideline discusses biosimilar product restrictions as well as various fees for product approval. The European Union's regulatory rules and MAA criteria are described in this article.

Keywords:
European Medicines Agency (EMA), European Commission (EC), Reference Medicinal Product (RMP), Chemistry Manufacturing Control (CMC), Marketing Authorization Application (MAA), Committee for Medicinal Products for Human Use (CHMP)

Article Details

How to Cite
JOSHI, S. S., BALAMURALIDHARA, V., & AKKI, A. (2021). DEVELOPMENT AND MARKETING AUTHORISATION OF BIOSIMILARS IN EU. Journal of International Research in Medical and Pharmaceutical Sciences, 16(3), 1-10. Retrieved from https://www.ikprress.org/index.php/JIRMEPS/article/view/6735
Section
Review Article

References

Available:https://biopharmaspec.com/?gclid=CjwKCAjwt8uGBhBAEiwAayu_9aP7fvhHlEG_BLRyq7Hn7jQYDGYZYFEEh364lLkFwIn5DtwdhPJ7vRoCSl8QAvD_BwE

Available:https://pubmed.ncbi.nlm.nih.gov/33396369/

Available:https://www.sciencedirect. com/science/article/pii/S135963491 3700016

European Medicines Agency - Biosimilar medicines-marketing authorization.

Available:https://www.ema.europa.eu/en/human-regulatory/marketingauthorisation/biosimilar-medicines-marketing-authorisation

Available:https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/biosimilar-medicines-marketing-authorisation

Volume 2B Notice to Applicants Medicinal products for human use.

Available:https://ec.europa.eu/health/sites/health/files/files/eudralex/vol2/b/update_200805/ctd_05-2008_en.pdf

Guideline on similar biological medicinal products containing biotechnology derived proteins as active substance: non-clinical and clinical issues.

Available:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf

Guideline on similar biological medicinal products containing biotechnology derived proteins as active substance: quality issues (revision 1).

Available:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500167838.pdf

QRD product information annotated template- EMA.

Available:https://www.ema.europa.eu/documents/template-form/qrd-productinformationannotated-template-english-version-10_en.pdf

Available:https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/obtaining-eu-marketing-authorisation-step-step

Tailored scientific advice to support step-by-step development of new biosimilars.

Available:https://www.ema.europa.eu/documents/other/tailoredscientificadvice-support-step-step-development-new-biosimilars_en.pdf

Available:https://www.ema.europa.eu/en/documents/other/tailored-scientific-advice-support-step-step-development-new-biosimilars_en.pdf

Available:https://www.ema.europa.eu/en/news/tailored-scientific-advice-support-step-step-development-new-biosimilars

Available:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192287/

Available:https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-advice-protocol-assistance

Available:https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-advice-protocol-assistance/requesting-scientific-advice-protocol-assistance-ema

Available:https://www.ema.europa.eu/en/documents/minutes/minutes-extraordinary-management-board-meeting-building-approval-process-ema-premises-amsterdam-28_en.pdf

Available:https://www.echr.coe.int/documents/handbook_data_protection_eng.pdf

Available:https://www.sciencedirect.com/science/article/pii/S2329050119300130

Available:https://globi-reg.com/wp-content/uploads/2018/01/Standard-Operating-Procedures.pdf